Technologies
This technology is a full-spectrum platform for treatment of immune-mediated neurodegenerative disorders which is capable of identifying biomarkers of disease, profiling the disease, and halting the responsible immune reaction.
Current diagnostic and treatment methods for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS) focus on protein aggregates rather than the autoimmune response involved in these diseases. Since these protein aggregates are confined to the brain, medical procedures targeting them are difficult to perform and limited in the information they provide. There is no effective screen to identify immune markers or immunotherapy targets for these diseases.
This technology uses a patient’s T cells and genetic information to screen for biomarkers of neurodegenerative disease. Using only blood samples from the patient, this technology enables identification of autoantigens driving the disease and subsequent targeting of those autoantigens for immunotherapy treatment. These next-generation approaches allow for personalized characterization of neurodegenerative diseases and targeting of patient-specific autoantigens.
This technology has been validated with human primary immune cells.
David Sulzer, Ph.D. and [Alessandro Sette, Ph.D.] (https://www.lji.org/faculty-research/labs/sette/#overview)
IR CU16214, CU17340, CU17354, CU17357
Licensing Contact: Jerry Kokoskha